{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:01:05Z","timestamp":1757617265085,"version":"3.44.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Tumor\/node\/metastasis staging and prognostic index (PI) are used to predict prognosis and guide treatment for anaplastic thyroid carcinoma (ATC). With the advent of treatments, such as BRAF\/MEK inhibitors and immune checkpoint inhibitors, dynamic markers to assess disease status and treatment efficacy are needed. This study examined the utility of PI as a dynamic marker for ATC treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study investigated 20 patients with ATC who were treated aggressively from January 2011 to December 2022. Patients were categorized into low-, high-, low-, and high-high groups according to the PI before and after treatment. Survival was then compared between the groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median overall survival was not reached for the Low\u2013Low, 363\u00a0days for the High\u2013Low, 158.5\u00a0days for the Low\u2013High, and 90.5\u00a0days for the High\u2013High groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Among the 13 patients with an initially high PI, 6 patients achieved a low PI during treatment, but three showed subsequent increases. Categorizing PI further into decreased, temporarily decreased, and non-decreased groups, median overall survival was 363\u00a0days, 158.5\u00a0days, and 87\u00a0days, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>PI is a critical prognostic indicator that facilitates treatment decision-making for ATC. PI may also have potential as a dynamic marker for assessing the disease status and treatment efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00595-024-02991-y","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T13:59:15Z","timestamp":1736171955000},"page":"1024-1031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamics of the prognostic index during the course of treatment for anaplastic thyroid carcinoma"],"prefix":"10.1007","volume":"55","author":[{"given":"Masaomi","family":"Sen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Kazusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Saitou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuta","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoo","family":"Jikuzono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwao","family":"Sugitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"2991_CR1","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma. JAMA Oncol. 2020;6:1397\u2013404.","journal-title":"JAMA Oncol"},{"key":"2991_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s002680020166","volume":"25","author":"I Sugitani","year":"2001","unstructured":"Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 2001;25:617\u201322.","journal-title":"World J Surg"},{"key":"2991_CR3","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.surg.2011.09.005","volume":"150","author":"Y Orita","year":"2011","unstructured":"Orita Y, Sugitani I, Amemiya T, Fujimoto Y. Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma. Surgery. 2011;150:1212\u20139.","journal-title":"Surgery"},{"issue":"Suppl 3","key":"2991_CR4","first-page":"1","volume":"35","author":"The JAES\/JSTS Task Force on the Guidelines for Thyroid Tumors","year":"2018","unstructured":"The JAES\/JSTS Task Force on the Guidelines for Thyroid Tumors. Clinical practice guidelines on the management of thyroid tumors 2018. Nihon Naibunpitu Kojosen Geka Gakkai Zasshi. 2018;35(Suppl 3):1\u201387.","journal-title":"Nihon Naibunpitu Kojosen Geka Gakkai Zasshi"},{"issue":"Suppl 2","key":"2991_CR5","first-page":"1","volume":"41","author":"The JAES Task Force on the Guidelines for Thyroid Tumors","year":"2024","unstructured":"The JAES Task Force on the Guidelines for Thyroid Tumors. Clinical practice guidelines on the management of thyroid tumors 2024. Nihon naibunpitu geka Gakkai zasshi. 2024;41(Suppl 2):1\u2013116.","journal-title":"Nihon naibunpitu geka Gakkai zasshi"},{"key":"2991_CR6","first-page":"256","volume-title":"TNM classification of malignant tumours","author":"JD Brierly","year":"2017","unstructured":"Brierly JD, Gospodarowics MK, Wittekind C, Union for International Cancer Control (UICC), et al. TNM classification of malignant tumours. 8th ed. Hoboken, NJ: Wiley; 2017. p. 256.","edition":"8"},{"key":"2991_CR7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2991_CR8","volume-title":"TNM classification of malignant tumours","author":"LH Sobin","year":"2009","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley; 2009.","edition":"7"},{"key":"2991_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hed.23295","volume":"36","author":"I Sugitani","year":"2014","unstructured":"Sugitani I, Hasegawa Y, Sugasawa M, Tori M, Higashiyama T, Miyazaki M, et al. Super-radical surgery for anaplastic thyroid carcinoma: a large cohort study using the Anaplastic Thyroid Carcinoma Research Consortium of Japan database. Head Neck. 2014;36:328\u201333.","journal-title":"Head Neck"},{"key":"2991_CR10","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1002\/cam4.5219","volume":"12","author":"H Yamazaki","year":"2023","unstructured":"Yamazaki H, Sugino K, Katoh R, Matsuzu K, Masaki C, Akaishi J, et al. Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma. Cancer Med. 2023;12:3027\u201335.","journal-title":"Cancer Med"},{"key":"2991_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1507\/endocrj.EJ20-0287","volume":"68","author":"S Ishihara","year":"2021","unstructured":"Ishihara S, Onoda N, Noda S, Tauchi Y, Morisaki T, Asano Y, et al. Treatment of anaplastic thyroid cancer with tyrosine kinase inhibitors targeted on the tumor vasculature: initial experience in clinical practice. Endocr J. 2021;68:63\u20138.","journal-title":"Endocr J"},{"key":"2991_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12020-020-02313-5","volume":"70","author":"H Yamazaki","year":"2020","unstructured":"Yamazaki H, Sugino K, Matsuzu K, Masaki C, Akaishi J, Hames K, et al. Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in anaplastic thyroid carcinoma. Endocrine. 2020;70:115\u201322.","journal-title":"Endocrine"},{"key":"2991_CR13","doi-asserted-by":"publisher","first-page":"852","DOI":"10.21037\/gs-20-871","volume":"10","author":"H Yamazaki","year":"2021","unstructured":"Yamazaki H, Iwasaki H, Suganuma N, Toda S, Masudo K, Nakayama H, et al. Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma. Gland Surg. 2021;10:852\u201360.","journal-title":"Gland Surg"},{"key":"2991_CR14","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.21873\/invivo.12113","volume":"34","author":"N Fukuda","year":"2020","unstructured":"Fukuda N, Toda K, Fujiwara YU, Wang X, Ohmoto A, Urasaki T, et al. Neutrophil-to-Lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with Lenvatinib. In Vivo. 2020;34:2859\u201364.","journal-title":"In Vivo"},{"key":"2991_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36:7\u201313.","journal-title":"J Clin Oncol"},{"key":"2991_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33:406\u201315.","journal-title":"Ann Oncol"},{"key":"2991_CR17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/thy.2022.0504","volume":"33","author":"X Zhao","year":"2023","unstructured":"Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, et al. Surgery after BRAF-directed therapy is associated with improved survival in BRAF. Thyroid. 2023;33:484\u201391.","journal-title":"Thyroid"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-024-02991-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-024-02991-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-024-02991-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:09:26Z","timestamp":1757128166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-024-02991-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2991"],"URL":"https:\/\/doi.org\/10.1007\/s00595-024-02991-y","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"type":"print","value":"0941-1291"},{"type":"electronic","value":"1436-2813"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"25 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki (revised in 2013). The protocol of this retrospective study was approved by the Institutional Review Board of Nippon Medical School Hospital (approval no. B-2023-803). All participants consented to participate in the study as they were provided with an opt-out option on the study website. All data were analyzed anonymously.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Consent for publication of this manuscript was obtained from the patients in an opt-out format based on the retrospective nature of this observational study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}